A Bioequivalence Study Of AG-013736 Tablets Under Fed Conditions In Healthy Volunteers

• Experimental: Sequence 1 (BABA)
  
  Treatment A: 5-mg Form IV tablet; Treatment B: 5-mg Form XLI tablets Subjects in this sequence will participate in 4 periods in the following order: B -> A -> B -> A
  Intervention: Drug: AG-013736
• Experimental: Sequence 2 (ABAB)
  
  Treatment A: 5-mg Form IV tablet; Treatment B: 5-mg Form XLI tablets Subjects in this sequence will participate in 4 periods in the following order: A -> B-> A -> B
  Intervention: Drug: AG-013736

Inclusion Criteria:

• Healthy male and/or female subjects between the ages of 21 and 47 years, inclusive (Healthy is defined as no clinically relevant abnormalities identified by a detailed medical history, full physical examination, including blood pressure and pulse rate measurement, 12-lead electrocardiogram (ECG) and clinical laboratory tests)
• Body Mass Index (BMI) of 17.5 to 30.5 kg/m2; and a total body weight >50 kg (110 lbs)
• An informed consent document signed and dated by the subject or a legally acceptable representative

Exclusion Criteria:

• Evidence of significant disease of the blood, kidney, endocrine system, lungs, gastrointestinal, heart, liver, psychiatric, neurologic, or allergic (including drug allergies, but excluding season allergies)
• Use of tobacco- or nicotine- containing products (or a positive urine cotinine test).
• Pregnant or nursing females and females of childbearing potential including those with tubal ligation